Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

All content curated by

Shyoko Honiden MD, MSc

Virginia Brady MD

Geoffrey Connors MD, FACP

See All Experts

Published in Respiratory Medicine

Journal Scan / Research · September 11, 2024

Efficacy of Elexacaftor–Tezacaftor–Ivacaftor in the Treatment of Cystic Fibrosis and CFTRN1303K in the US

The Lancet Respiratory Medicine

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Emmett Kistler MD

The Lancet Respiratory Medicine

Evaluation of elexacaftor-tezacaftor-ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial

Lancet Respir Med 2024 Aug 26;[EPub Ahead of Print], GM Solomon, RW Linnemann, R Rich, A Streby, B Buehler, E Hunter, K Vijaykumar, WR Hunt, JJ Brewington, A Rab, SP Bai, AL Westbrook, C McNicholas-Bevensee, J Hong, C Manfredi, C Barilla, S Suzuki, BR Davis, EJ Sorscher

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Efficacy of Elexacaftor–Tezacaftor–Ivacaftor in the Treatment of Cystic Fibrosis and CFTRN1303K in the US

Additional Info

Evaluation of elexacaftor-tezacaftor-ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial

Further Reading

Efficacy and Safety of Depemokimab in the Treatment of Patients With Severe Asthma With an Eosinophilic Phenotype

Impact of COVID-19 Pandemic on COPD Healthcare Use, Exacerbations, and Mortality

Associations of PRISm and RSP With Risk Factors, Morbidity, and Mortality

Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD

Prevalence of Critical Errors and Insufficient Peak Inspiratory Flow in Patients Hospitalized With COPD

Impact of Delayed Transition From Noninvasive to Invasive Mechanical Ventilation on Hospital Mortality in Immunocompromised Patients With Sepsis

Role of Biomarker Testing in Guiding Precision Medicine for Patients With Non–Small Cell Lung Cancer

Association Between Naloxone and Clinical Outcomes Among Patients With Out-of-Hospital Cardiac Arrest

Identification, Prevention, and Management of Complications Caused by Devices in the ICU

Safety and Tolerability of Bexotegrast in the Treatment of Patients With IPF

Impact of Age, Frailty, and Multimorbidity on the Effect of ICU Interventions

Recently Updated